Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. 40 years or older than 40 years；~2. Acute cerebral ischemic event due to：~   * Acute non-disabling ischemic stroke (NIHSS≤3 at the time of randomization)or，~  * TIA with moderate-to-high risk of stroke (ABCD2 score ≥ 4 at the time of randomization)；~3. Can be treated with study drug within 24 hours of symptoms onset\*(\*Symptom onset is defined by the last seen normal principle)；~4. CYP2C19 loss-of-function allele carriers；~5. Informed consent signed.~Exclusion Criteria~1. Malformation, tumor, abscess or other major non-ischemic brain disease (e.g., multiple sclerosis) on baseline head CT or MRI.~2. Isolated or pure sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.~3. Iatrogenic causes (angioplasty or surgery) of minor stroke or TIA.~4. Preceding moderate or severe dependency (modified Rankin scale \[mRS\] score 3-5).~5. Contraindication to clopidogrel, ticagrelor or aspirin~   * Known allergy~  * Severe renal (creatinine exceeding 1.5 times of the upper limit of normal range) or hepatic (ALT or AST \> twice the upper limit of normal range) insufficiency~  * Severe cardiac failure (NYHA level: III to IV)~  * History of hemostatic disorder or systemic bleeding~  * History of thrombocytopenia or neutropenia~  * History of drug-induced hematologic disorder or hepatic dysfunction~  * Low white blood cell (\<2×109/L) or platelet count (\<100×109/L)~6. Hematocrit (HCT) \<30%~7. Clear indication for anticoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, prosthetic cardiac valves known or suspected endocarditis)~8. History of intracranial hemorrhage or amyloid angiopathy~9. History of aneurysm (including intracranial aneurysm and peripheral aneurysm)~10. History of asthma or COPD (chronic obstructive pulmonary disease)~11. High-risk for bradyarrhythmia (first-degree or second-degree AV block caused by sinus node disease, and brady-arrhythmic syncope without pacemaker)~12. History of hyperuricemia nephropathy~13. Anticipated requirement for long-term (\>7 days) non-steroidal anti-inflammatory drugs (NSAIDs)~14. Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months~15. Scheduled for surgery or interventional treatment requiring study drug cessation~16. Severe non-cardiovascular comorbidity with life expectancy \< 3 months~17. Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders~18. Dual antiplatelet treatment (or more than two antiplatelet agents) in 72 hours before randomization~19. Current treatment (last dose given within 10 days before randomization) with heparin therapy or oral anti coagulation~20. Intravenous thrombolytic therapy (such as intravenous rtPA) or mechanical thrombectomy within 24 hours prior to randomization~21. Gastrointestinal bleed within 3 months or major surgery within 30 days~22. Diagnosis or suspicious diagnosis of acute coronary syndrome~23. Participation in another clinical study with an experimental product during the last 30 days~24. Currently receiving an experimental drug or device~25. Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor plus Aspirin Group (Type: EXPERIMENTAL): Ticagrelor of loading dosing of 180mg followed by 90mg bid for 3 months plus aspirin of loading dose of 75-300mg followed by 75mg daily for 21 days
- Clopidogrel plus Aspirin Group (Type: ACTIVE_COMPARATOR): Clopidogrel of loading dosing of 300mg followed by 75mg daily for 3 months plus aspirin loading dose of 75-300mg followed by 75mg daily for 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).